ID   NYH/187/162
AC   CVCL_0B24
SY   NYH/187; NYH/ICRF-187-1
DR   Wikidata; Q54931215
RX   PubMed=10416608;
RX   PubMed=12044890;
CC   Selected for resistance to: ChEBI; CHEBI_50223; (+)-dexrazoxane (Cardioxane; ICRF-187).
CC   Sequence variation: Mutation; HGNC; HGNC:11989; TOP2A; Simple; p.Arg162Gln (c.485G>A); Zygosity=Homozygous; Note=Responsible for resistance to bisdioxopiperazine drugs (PubMed=10416608).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Unexplicit; Ex8del14; Zygosity=Unspecified (from parent cell line).
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C4917; Lung small cell carcinoma
DI   ORDO; Orphanet_70573; Small cell lung cancer
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_8207 ! GLC-2
SX   Male
AG   41Y
CA   Cancer cell line
DT   Created: 10-04-15; Last updated: 10-04-25; Version: 10
//
RX   PubMed=10416608;
RA   Wessel I., Jensen L.H., Jensen P.B., Falck J., Rose A., Roerth M.,
RA   Nitiss J.L., Sehested M.;
RT   "Human small cell lung cancer NYH cells selected for resistance to the
RT   bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187
RT   demonstrate a functional R162Q mutation in the Walker A consensus ATP
RT   binding domain of the alpha isoform.";
RL   Cancer Res. 59:3442-3450(1999).
//
RX   PubMed=12044890; DOI=10.1016/S0014-5793(02)02805-3;
RA   Wessel I., Jensen L.H., Renodon-Corniere A., Sorensen T.K.,
RA   Nitiss J.L., Jensen P.B., Sehested M.;
RT   "Human small cell lung cancer NYH cells resistant to the
RT   bisdioxopiperazine ICRF-187 exhibit a functional dominant Tyr165Ser
RT   mutation in the Walker A ATP binding site of topoisomerase II alpha.";
RL   FEBS Lett. 520:161-166(2002).
//